| Identification | Back Directory | [Name]
(E)-3-(furan-2-yl)-N-(2-pyridin-4-yl-1,3-benzoxazol-5-yl)prop-2-enamide | [CAS]
332063-87-3 | [Synonyms]
SW157765
(E)-3-(furan-2-yl)-N-(2-(pyridin-4-yl)benzo[d]oxazol-5-yl)acrylamide
(E)-3-(furan-2-yl)-N-(2-pyridin-4-yl-1,3-benzoxazol-5-yl)prop-2-enamide | [Molecular Formula]
C19H13N3O3 | [MDL Number]
MFCD01539854 | [MOL File]
332063-87-3.mol | [Molecular Weight]
331.32 |
| Chemical Properties | Back Directory | [Boiling point ]
577.8±50.0 °C(Predicted) | [density ]
1.364±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 25 mg/mL (75.46 mM; ultrasonic and warming and heat to 60°C) | [form ]
Solid | [pka]
11.48±0.43(Predicted) | [color ]
Brown to reddish brown |
| Hazard Information | Back Directory | [Uses]
SW157765 is a selective non-canonical glucose transporter GLUT8 (SLC2A8) inhibitor. KRAS/KEAP1 double mutant NSCLC cells are selectively sensitive to the SW157765, due to the convergent consequences of dual KRAS and NRF2 modulation of metabolic and xenobiotic gene regulatory programs[1][2]. | [Biological Activity]
SW157765 is a selective inhibitor of the non-canonical glucose transporter GLUT8 (SLC2A8)which exhibit potent anticancer activity on KRAS/KEAP1 mutant NSCLC cells th at selectively depend on GLUT8 for glucose intake to support serine biosynthesis. | [References]
[1] Pine SR, et al. Identifying therapeutic vulnerabilities in lung cancer: application of a chemistry-first approach. Transl Lung Cancer Res. 2018;7(Suppl 3):S265-S269. DOI:10.21037/tlcr.2018.09.10
[2] McMillan EA, et al. Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell. 2018;173(4):864-878.e29. DOI:10.1016/j.cell.2018.03.028 |
|
| Company Name: |
ChemShuttle, Inc.
|
| Tel: |
0150-83588313-811 18800520310 |
| Website: |
www.jiehuapharma.com/ |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
| Company Name: |
PHARMEKS Ltd.
|
| Tel: |
+7 (495) 702-9648 |
| Website: |
www.pharmeks.com |
|